

Martin Perez-Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/35543/publications.pdf>

Version: 2024-02-01

31
papers

348
citations

840776

11
h-index

839539

18
g-index

31
all docs

31
docs citations

31
times ranked

547
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Effect of Botulinum Toxin A on Proliferation and Apoptosis in the T47D Breast Cancer Cell Line. Asian Pacific Journal of Cancer Prevention, 2013, 14, 891-894. | 1.2 | 41 |
| 2 | miR-485 Acts as a Tumor Suppressor by Inhibiting Cell Growth and Migration in Breast Carcinoma T47D Cells. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3757-3760. | 1.2 | 32 |
| 3 | An ecto-protein tyrosine phosphatase of Entamoeba histolytica induces cellular detachment by disruption of actin filaments in HeLa cells. International Journal for Parasitology, 2003, 33, 663-670. | 3.1 | 29 |
| 4 | Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes, 2017, 8, 217. | 2.4 | 24 |
| 5 | miR-153 Silencing Induces Apoptosis in the MDA-MB-231 Breast Cancer Cell Line. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2983-2986. | 1.2 | 24 |
| 6 | Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert Opinion on Therapeutic Patents, 2019, 29, 587-593. | 5.0 | 23 |
| 7 | LAG-3 antagonists by cancer treatment: a patent review. Expert Opinion on Therapeutic Patents, 2019, 29, 643-651. | 5.0 | 22 |
| 8 | In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunology, 2001, 23, 599-606. | 1.5 | 18 |
| 9 | Cervical Cancer Trends in Mexico: Incidence, Mortality and Research Output. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8689-8692. | 1.2 | 18 |
| 10 | Female Breast Cancer Incidence and Mortality in Mexico, 2000-2010. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1477-1479. | 1.2 | 15 |
| 11 | Mexican Breast Cancer Research Output, 2003-2012. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5921-5923. | 1.2 | 14 |
| 12 | Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649. Expert Opinion on Therapeutic Patents, 2019, 29, 921-924. | 5.0 | 12 |
| 13 | Bursera copallifera Extracts Have Cytotoxic and Migration-Inhibitory Effects in Breast Cancer Cell Lines. Integrative Cancer Therapies, 2018, 17, 654-664. | 2.0 | 11 |
| 14 | Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054. Expert Opinion on Therapeutic Patents, 2020, 30, 487-494. | 5.0 | 9 |
| 15 | OX40 agonists for cancer treatment: a patent review. Expert Opinion on Therapeutic Patents, 2021, 31, 81-90. | 5.0 | 8 |
| 16 | Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1. Expert Opinion on Therapeutic Patents, 2019, 29, 311-314. | 5.0 | 6 |
| 17 | Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739. Expert Opinion on Therapeutic Patents, 2020, 30, 307-311. | 5.0 | 6 |
| 18 | Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 85-94. | 1.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Innovation Status of Gene Therapy for Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4133-4136. | 1.2 | 5 |
| 20 | Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536. Expert Opinion on Therapeutic Patents, 2020, 30, 83-86. | 5.0 | 4 |
| 21 | Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors. Pharmaceutical Patent Analyst, 2020, 9, 149-154. | 1.1 | 4 |
| 22 | Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1. Expert Opinion on Therapeutic Patents, 2019, 29, 481-485. | 5.0 | 3 |
| 23 | Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652. Expert Opinion on Therapeutic Patents, 2020, 30, 159-162. | 5.0 | 3 |
| 24 | Neurophysiological Mechanisms Related to Pain Management in Bone Tumors. Current Neuropharmacology, 2021, 19, 308-319. | 2.9 | 3 |
| 25 | Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232. Expert Opinion on Therapeutic Patents, 2020, 30, 723-727. | 5.0 | 2 |
| 26 | Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents. Recent Patents on Anti-Cancer Drug Discovery, 2017, 12, 81-93. | 1.6 | 2 |
| 27 | Emerging Drugs for the Treatment of Breast Cancer Brain Metastasis: A Review of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 348-359. | 1.6 | 2 |
| 28 | Drug repurposing of adapalene for melanoma treatment. Pharmaceutical Patent Analyst, 2022, 11, 9-14. | 1.1 | 2 |
| 29 | Bispecific anti-OX40/5T4 antibodies for cancer treatment. Pharmaceutical Patent Analyst, 2021, 10, 59-66. | 1.1 | 1 |
| 30 | Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody. Pharmaceutical Patent Analyst, 2021, 10, 67-72. | 1.1 | 0 |
| 31 | Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. Pharmaceutical Patent Analyst, 2021, 10, 245-250. | 1.1 | 0 |